RecruitingPhase 2NCT05288790
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
Sponsor
Vanderbilt University Medical Center
Enrollment
250 participants
Start Date
Sep 18, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
Among people living with HIV, heavy drinking increases the risk of heart disease and death. Studies suggest that alcohol changes the number and kind of bacteria in your gut and these changes increase the risk of heart disease and death. This randomized controlled trial will determine whether a pill containing healthy gut bacteria can increase the number good bacteria in the gut, lower levels of inflammation, and lower the risk of heart disease and death.
Eligibility
Min Age: 18 YearsMax Age: 89 Years
Inclusion Criteria1
- HIV infected
Exclusion Criteria1
- Not fluent in English
Interventions
DIETARY_SUPPLEMENTProbiotic
Dietary supplement
DIETARY_SUPPLEMENTPlacebo
Placebo sachet
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05288790
Related Trials
A Randomized Clinical Trial to Evaluate Solutions for the Management of Virologic Failure on TLD in Sub-Saharan Africa
NCT053737583 locations
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT070644731153 locations
The Prevalence, Disease Burden and Prognosis of COPD in Patients With Cardiovascular Diseases
NCT0690977369 locations
Diabetes and Heart Disease Risk in Blacks
NCT000018531 location
Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT) in Subjects With Uncontrolled Hypertension
NCT0711595319 locations